AMERICAN SOCIETY OF CLINICAL ONCOLOGY TECHNOLOGY ASSESSMENT ON THE USE OF AROMATASE INHIBITORS AS ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: STATUS REPORT

WINER, E.P., & HUDIS, C.. (2005). AMERICAN SOCIETY OF CLINICAL ONCOLOGY TECHNOLOGY ASSESSMENT ON THE USE OF AROMATASE INHIBITORS AS ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: STATUS REPORT. JOURNAL OF CLINICAL ONCOLOGY, 23(3), 619-629. SID. https://sid.ir/paper/638812/en

WINER E.P., HUDIS C.. AMERICAN SOCIETY OF CLINICAL ONCOLOGY TECHNOLOGY ASSESSMENT ON THE USE OF AROMATASE INHIBITORS AS ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: STATUS REPORT. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2005;23(3):619-629. Available from: https://sid.ir/paper/638812/en

E.P. WINER, and C. HUDIS, “AMERICAN SOCIETY OF CLINICAL ONCOLOGY TECHNOLOGY ASSESSMENT ON THE USE OF AROMATASE INHIBITORS AS ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE BREAST CANCER: STATUS REPORT,” JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 3, pp. 619–629, 2005, [Online]. Available: https://sid.ir/paper/638812/en